Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 2Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Locally Recurrent Skin Squamous Cell Carcinoma 1Leukemia, Plasma Cell 1Endometrial Neoplasms 1Classic Follicular Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 50Paclitaxel 48Cisplatin 39Gemcitabine 31Erlotinib Hydrochloride 30Radiotherapy 28Docetaxel 24Taxes 21Specimen Handling 20Magnetic Resonance Spectroscopy 20Vinorelbine 16Pemetrexed 12Etoposide 12Bevacizumab 12Radiation 10Gefitinib 10aldesleukin 8Platinum 8Bortezomib 8Biopsy 8Vinblastine 7Azacitidine 71,2-diaminocyclohexaneplatinum II citrate 7pembrolizumab 6atezolizumab 6Observation 6Immunoglobulin G 6Disulfides 6Cyclophosphamide 6Chemotherapy, Adjuvant 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Non-Small-Cell Lung × Hyaluronoglucosaminidase × Clear all
NCT07388524 2026-05-13

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
336 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡